RobertoOrtizMDAAHIVS

PubMed

• 20 citations
  Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
  Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson K Wurapa, Moti Ramgopal, Peter A. Leone, Jessica E. Matthews, Marybeth Dalessandro, Mark R. Un...> ;AIDS. 2021 Oct 1
• 36 citations
  Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy-naive adults with HIV-1 infection.
  Pedro Cahn, Juan Sierra Madero, Jose R. Arribas, Andrea Antinori, Roberto Ortiz, Amanda Clarke, Chien-Ching Hung, Jürgen K. Rockstroh, Pierre-Marie Girard, Jörg Siever...> ;AIDS. 2021 Sep 15
• 101 citations
  Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomiz...
  Pedro Cahn, Juan Sierra Madero, Jose R. Arribas, Andrea Antinori, Roberto Ortiz, Amanda Clarke, Chien-Ching Hung, Jürgen K. Rockstroh, Pierre-Marie Girard, Jörg Siever...> ;Journal of Acquired Immune Deficiency Syndromes. 2020 Mar 1
• 16 citations
  Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumara...
  Anthony Mills, G. Crofoot, Roberto Ortiz, Bruce Rashbaum, William J. Towner, Douglas J. Ward, Cynthia Brinson, Rohit N. Kulkarni, William Garner, Ramin Ebrahimi, Huyen...> ;HIV Clinical Trials. 2014 Dec 22
• 171 citations
  Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: A randomized phase 2 study
  Paul E. Sax, Andrew R. Zolopa, Indira Brar, Richard Elion, Roberto Ortiz, Frank A. Post, Hui Wang, Christian Callebaut, Hal Martin, Marshall W. Fordyce, Scott McCallister> ;Journal of Acquired Immune Deficiency Syndromes. 2014 Sep 1
• 375 citations
  Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label ...
  Bonaventura Clotet, Judith Feinberg, Jan van Lunzen, Marie Aude Khuong-Josses, Andrea Antinori, Irina Dumitru, Vadim Pokrovskiy, Jan Fehr, Roberto Ortiz, Michael S. Sa...> ;Lancet. 2014 Jun 28
• 308 citations
  Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
  Roberto Ortiz, Edwin DeJesus, Homayoon Khanlou, Evgeniy Voronin, Jan van Lunzen, Jaime Andrade-Villanueva, Jan Fourie, Sandra De Meyer, Martine De Pauw, Eric Lefebvre,...> ;AIDS. 2008 Jul 31
• 20 citations
  Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-d...
  Richard Elion, Calvin J. Cohen, Douglas J. Ward, Peter Ruane, Roberto Ortiz, Y. Sunila Reddy, Ramin Ebrahimi, Damian J McColl, Brian P. Kearney, Alvan Fisher, John P. ...> ;HIV Clinical Trials. 2008 Apr 21
• Join now to see all